Eledon Pharmaceuticals Inc (ELDN) Stock Price, Quote & News

Company Profile

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for th...

Industry: Biotechnology

Sector: Healthcare

Phone: 949 238 8090

Website: eledon.com

Address:

19800 MacArthur Boulevard, Suite 250, Irvine, United States

Ontherag Feb. 24 at 3:47 AM

$ELDN The bestow trial also confirmed that new onset of diabieties was basically ameliorated with use of Tego. They should focus 100% on this.

0 · Reply

Veraton Feb. 23 at 9:33 PM

$ELDN 2.57-2.65 next big wall

0 · Reply

Veraton Feb. 23 at 9:31 PM

$ELDN What's the MA for the last 60 days?

0 · Reply

BriOnH Feb. 23 at 9:22 PM

$ELDN C&H formed. High statistical chance of breakout if it can clear resistance. Failure rates are pretty low on this pattern, but I have seemed to catch a about 3 failures in a row on this pattern, so it does happen.

0 · Reply

red1 Feb. 23 at 9:10 PM

$ELDN 💪

0 · Reply

Veraton Feb. 23 at 8:41 PM

$ELDN definitely everything is in the way you transmit the data

0 · Reply

cwork Feb. 23 at 7:39 PM

$ELDN https://www.type1strong.org/blog-post/tegoprubart-is-a-game-changer-in-islet-cell-transplantation-surgery-for-t1d-patients

0 · Reply

cwork Feb. 23 at 6:53 PM

$ELDN Interview with a patient that has been cured from T1D all because of Eledon’s drug Tegoprubart! https://m.youtube.com/watch?v=C1TQrhINmnU&pp=0gcJCUABo7VqN5tD&fbclid=IwQ0xDSwQJgRVleHRuA2FlbQIxMQBzcnRjBmFwcF9pZAo2NjI4NTY4Mzc5AAEeaWtmT4OR2kP-keKkombcr6PJ2oU5o0cS5PNDCgJnW7rYtbaB9WdJkMpF-6k_aem_7-d_RTW1F_CQABmzoDEV5g

0 · Reply

cwork Feb. 22 at 6:35 PM

$ELDN Explains how to contact your member of the senate in the help committee to push forward the islet act to get approved! We need everyone to keep calling, emailing and reaching out! https://www.tiktok.com/t/ZP8xYHwv5/

0 · Reply

red1 Feb. 22 at 6:26 PM

$ELDN big biotech companies buy small pre clinical stage companies much sooner just before they’re value becomes too expensive…. ELDN is at that stage… the just before stage

2 · Reply

Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Jan 23, 2026, 7:00 AM EST - 4 weeks ago

Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium

Jan 8, 2026, 4:05 PM EST - 6 weeks ago

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook

Dec 1, 2025, 7:00 AM EST - 3 months ago

Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference

Nov 18, 2025, 4:05 PM EST - 3 months ago

Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

Nov 17, 2025, 1:07 PM EST - 3 months ago

Eledon Pharmaceuticals, Inc. (ELDN) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript

Nov 14, 2025, 5:00 PM EST - 3 months ago

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results

Nov 12, 2025, 7:56 AM EST - 3 months ago

Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Nov 11, 2025, 5:26 PM EST - 3 months ago

Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Nov 7, 2025, 2:36 PM EST - 3 months ago

Eledon Pharmaceuticals, Inc. (ELDN) Discusses Phase II BESTOW Trial Results and Advances in Transplantation Immunosuppression Transcript

Nov 7, 2025, 1:36 PM EST - 3 months ago

Eledon Pharmaceuticals' Lead Asset Fails In Mid-Stage Study, But Pushes Forward With Pivotal Study

Nov 6, 2025, 6:30 PM EST - 3 months ago

Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology's Kidney Week 2025 Annual Meeting

Nov 5, 2025, 7:00 AM EST - 3 months ago

Eledon Pharmaceuticals to Present at Guggenheim Second Annual Healthcare Innovation Conference

Oct 17, 2025, 7:00 AM EDT - 4 months ago

Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting

Sep 24, 2025, 4:05 PM EDT - 5 months ago

Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association

Aug 29, 2025, 7:00 AM EDT - 6 months ago

Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025

Aug 14, 2025, 4:20 PM EDT - 6 months ago

Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results

Aug 6, 2025, 4:01 PM EDT - 7 months ago

Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Jul 30, 2025, 4:05 PM EDT - 7 months ago

Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025

Jul 17, 2025, 4:01 PM EDT - 7 months ago

Updated Data from Eledon Pharmaceuticals' Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025

Jun 25, 2025, 4:01 PM EDT - 8 months ago

Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City

May 14, 2025, 4:01 PM EDT - 10 months ago

Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results

May 6, 2025, 1:15 PM EDT - 10 months ago

Undercovered Dozen: Gevo, Eledon, Dorian, Iridium +

GEVO IRDM LPG

May 3, 2025, 8:15 AM EDT - 10 months ago

Eledon: A Company With Good Early Data In Kidney Transplant Rejection And A Full Balance Sheet

Mar 20, 2025, 4:01 PM EDT - 1 year ago

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results

Mar 4, 2025, 4:05 PM EST - 1 year ago

Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference

Feb 7, 2025, 10:00 AM EST - 1 year ago

Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human

Jan 29, 2025, 4:05 PM EST - 1 year ago

Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference

Jan 28, 2025, 11:27 AM EST - 1 year ago

Eledon Pharmaceuticals: At The Forefront Of The Organ Transplant Management Business

Jan 13, 2025, 7:00 AM EST - 1 year ago

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook

Nov 12, 2024, 4:01 PM EST - 1 year ago

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results

Oct 29, 2024, 3:51 PM EDT - 1 year ago

Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart

Oct 29, 2024, 7:46 AM EDT - 1 year ago

Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Oct 29, 2024, 7:45 AM EDT - 1 year ago

Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

Sep 11, 2024, 4:05 PM EDT - 1 year ago

Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference

Sep 4, 2024, 7:00 AM EDT - 1 year ago

Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients

Aug 14, 2024, 5:21 PM EDT - 1 year ago

Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results

Jul 29, 2024, 7:00 AM EDT - 1 year ago

Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection

Jul 2, 2024, 4:05 PM EDT - 1 year ago

Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism

May 9, 2024, 7:30 AM EDT - 1 year ago

Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results

May 9, 2024, 7:00 AM EDT - 1 year ago

Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress

May 7, 2024, 7:05 AM EDT - 1 year ago

Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection

Mar 28, 2024, 4:01 PM EDT - 2 years ago

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

Mar 25, 2024, 4:56 PM EDT - 2 years ago

Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

Mar 21, 2024, 10:31 AM EDT - 2 years ago

Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human

Feb 13, 2024, 7:01 PM EST - 2 years ago

Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 4, 2024, 4:40 PM EST - 2 years ago

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook

Nov 29, 2023, 4:05 PM EST - 2 years ago

Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference

Nov 9, 2023, 4:01 PM EST - 2 years ago

Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results

Nov 8, 2023, 4:05 PM EST - 2 years ago

Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference

Ontherag Feb. 24 at 3:47 AM

$ELDN The bestow trial also confirmed that new onset of diabieties was basically ameliorated with use of Tego. They should focus 100% on this.

0 · Reply

Veraton Feb. 23 at 9:33 PM

$ELDN 2.57-2.65 next big wall

0 · Reply

Veraton Feb. 23 at 9:31 PM

$ELDN What's the MA for the last 60 days?

0 · Reply

BriOnH Feb. 23 at 9:22 PM

0 · Reply

red1 Feb. 23 at 9:10 PM

$ELDN 💪

0 · Reply

Veraton Feb. 23 at 8:41 PM

$ELDN definitely everything is in the way you transmit the data

0 · Reply

cwork Feb. 23 at 7:39 PM

$ELDN https://www.type1strong.org/blog-post/tegoprubart-is-a-game-changer-in-islet-cell-transplantation-surgery-for-t1d-patients

0 · Reply

cwork Feb. 23 at 6:53 PM

0 · Reply

cwork Feb. 22 at 6:35 PM

0 · Reply

red1 Feb. 22 at 6:26 PM

$ELDN big biotech companies buy small pre clinical stage companies much sooner just before they’re value becomes too expensive…. ELDN is at that stage… the just before stage

2 · Reply

Veraton Feb. 22 at 6:12 PM

$ELDN If the islet act becomes a reality it will be an extraordinary catalyst... When Is supposed to be voted?

0 · Reply

Penny_stock_Raid_Boss Feb. 22 at 5:23 PM

$ELDN they probably sold for tax loss, the date of Feb is misleading because the form implies 0 shares by the 31th december 2025. They 99% chance sold because it would have been stupid for them not to harvest tax loss, not because eledon "maybe will dilute but maybe not i don't know", it's not how things get decided. Beside, if they really "must dilute" guess who gets the cheapies? Funds such as RA CAPITAL. It's legit so funny to look at random retailer thinking that funds thinks like random retailers.

0 · Reply

cwork Feb. 22 at 4:13 PM

$ELDN Amazing update from another patient on tego https://www.tiktok.com/t/ZP8xYawxJ/

0 · Reply

Veraton Feb. 22 at 1:42 PM

$ELDN it is but we need to see results after 10-12-14 months... And definitely enroll ad many patients as possible... This 10 patients are not Statistically significant... Good for them,,, very happy for them... But we have a longgggggg road ahead...

1 · Reply

cwork Feb. 22 at 12:25 AM

$ELDN Tegoprubart is a miracle drug! 💯💯

0 · Reply

Ontherag Feb. 21 at 6:16 PM

$ELDN RA capital sold out. I think they realize that Eledon will have to raise another 100M+ to fund the phase 3 trial for kidney transplant. Our CEO also diluted 40% just to fund trials this year and get FDA alignment. That being said, I’m in this stock for T1D and potential partnerships (ie Vertex) and also the islet bill moving through Congress. I think that’s the ultimate play. If they don’t get a partnership or gain non-dilutive funding by end of Q3, I will be out because they will have to raise again and take another 50% cut. Be smart on this one. GL.

1 · Reply

cwork Feb. 21 at 5:58 PM

$ELDN https://www.tiktok.com/t/ZP8xNC7HJ/ Everyone needs to help and work to get the islet act passed!!

0 · Reply

MercyPerson841 Feb. 21 at 6:24 AM

$ELDN Eledon Pharmaceuticals develops immunology therapies. Clinical outcomes drive valuation. Early-stage risk remains high.

0 · Reply

OfficialStocktwitsUser Feb. 20 at 9:49 PM

$ELDN RSI: 49.52, MACD: 0.0454 Vol: 0.08, MA20: 2.14, MA50: 1.90 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

cwork Feb. 20 at 8:05 PM

$ELDN https://www.facebook.com/share/r/1DFen4L2M5/?mibextid=wwXIfr

0 · Reply

Atomeye Feb. 20 at 2:43 PM

$ELDN Thinking of starting a position here. As a person who has lived with T1D for over 30 years, this looks very promising.

0 · Reply

Chasetae Feb. 19 at 10:54 PM

$ELDN bought a few more

0 · Reply

Market Cap	131.25M
Revenue (ttm)	0.00
Net Income (ttm)	-36.18M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	652,000
Avg Vol	761,472
Day's Range	N/A - N/A
Shares Out	59.93M
Stochastic %K	97%
Beta	0.89
Analysts	Strong Sell
Price Target	$8.00